Use of Mobile Teledermatology in the Care of Acne Patients
NCT ID: NCT01399970
Last Updated: 2014-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
69 participants
INTERVENTIONAL
2011-04-30
2013-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The superiority of mobile care in comparison to conventional, outpatient care will be investigated regarding
1. effectiveness: Global evaluation Acne (GEA) score -response at week 24
2. safety: drop out rates and medication side effects
3. overall patient satisfaction with acne care and therapy
4. overall physician satisfaction with mobile acne care
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Use of Teledermatology in the Treatment of Patients With Severe Acne on Isotretinoin
NCT03707236
A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris
NCT02395549
Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel
NCT02850003
Pharmacokinetic Study of MTC896 Gel in Subjects With Acne
NCT02293018
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
NCT00666900
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Outpatient Consultation Arm (OCA)
Conventional in Office Care
Outpatient Consultation Arm (OCA)
Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.
Mobile Teleconsultation Arm (MTA)
Mobile Teledermatology Care
Mobile Teleconsultation Arm (MTA)
In addition to a face-to-face visit at baseline, patients will conduct "mobile visits" at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mobile Teleconsultation Arm (MTA)
In addition to a face-to-face visit at baseline, patients will conduct "mobile visits" at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines.
Outpatient Consultation Arm (OCA)
Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* with facial acne
* requiring systemic isotretinoin treatment (GEA-Score: 3-5)
* with basic handy skills
* with a signed consent form
Exclusion Criteria
* Withdrawal of informed consent
* Non-compliance, failure to comply with protocol requirements
12 Years
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Bank of Austria
OTHER_GOV
Medical University of Graz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rainer Hofmann-Wellenhof, MD
Prof. Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rainer Hofmann-Wellenhof, MD
Role: STUDY_DIRECTOR
Department of Dermatology, Medical University of Graz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Dermatology, Medical University of Graz
Graz, Graz, Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.